USPTO serial 79425440
Serial No. 79425440
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 28, 2026
- Examiner
- OH, HYUN-JUNG
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79425440?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Kreider Gaunt
Karen Kreider Gaunt Dinsmore & Shohl LLP255 E. 5th Street, Suite 1900Cincinnati, OH 45202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastroenteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases and syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone | ACTIVE | — |
| 010 | Medical devices used for the administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices used for the for administration of pharmaceuticals for the treatment of tumours; medical devices used for the for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices used for the for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices used for the administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices used for the administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices used for the administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices used for the administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices used for the administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices used for the administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices used for the administration of pharmaceuticals for metabolic disorders; medical devices used for the administration of pharmaceuticals for the treatment of acromegaly; medical devices used for the administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices used for the administration of pharmaceuticals for the treatment of respiratory diseases and syndrome; medical devices used for the administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices used for the administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices used for the administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices used for the administration of pharmaceuticals intended to block growth hormone; medical syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical syringes for administration of pharmaceuticals for the treatment of tumours; medical syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; medical syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic tumours; medical syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; medical syringes for administration of pharmaceuticals for the treatment of metabolic disorders; medical syringes for administration of pharmaceuticals for the treatment of acromegaly; medical syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; medical syringes for administration of pharmaceuticals for the treatment of respiratory diseases and syndrome; medical syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical syringes for administration of pharmaceuticals intended to block growth hormone; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens in the nature of microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices for subcutaneous administration of pharmaceuticals, namely infusion and injection devices; medical devices for parenteral administration of pharmaceuticals, namely infusion and injection devices; medical devices for injection of pharmaceutical depots, namely, medical fluid injectors; devices for subcutaneous injection of pharmaceutical depot, namely, medical fluid injectors; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot being pharmaceuticals; medical syringes for subcutaneous administration and injections of pharmaceuticals; medical syringes for parenteral administration and injections of pharmaceuticals; medical syringes for injection of pharmaceutical depots; medical syringes for subcutaneous injection of pharmaceutical depot; medical syringes for parenteral injection of pharmaceutical depot; medical syringes for injections of injection fluids; medical syringes for injection of injection depot; medical syringes for injections; medical syringes for medical uses; pens in the nature of microneedle dermal pens for subcutaneous administration of pharmaceuticals; pens in the nature of microneedle dermal pens for parenteral administration of pharmaceuticals; pens in the nature of microneedle dermal pens for injection of pharmaceutical depots; pens in the nature of microneedle dermal pens for subcutaneous injection of pharmaceutical depot; pens in the nature of microneedle dermal pens for parenteral injection of pharmaceutical depot; pens in the nature of microneedle dermal pens for injection of injection fluids; pens in the nature of microneedle dermal pens for injection of injection depot; pens in the nature of microneedle dermal pens for injections; pens in the nature of microneedle dermal pens for medical uses | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 3, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 28, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 28, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 28, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 9, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 9, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 3, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 14, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 8, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 8, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 7, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 18, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 18, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 3, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 2, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 6, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 6, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 5, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |